US-based biopharmaceutical firm Sage Therapeutics has begun dosing healthy volunteers in its Phase I clinical trial of SAGE-718.

SAGE-718 is an oral, oxysterol-based, N-methyl-D-aspartate (NMDA) receptor, positive allosteric modulator (PAM).

The positive modulation of NMDA receptors reportedly has the potential for treating disorders characterised by cognitive, neurological and behavioural symptoms.

The double-blind, placebo-controlled, single ascending dose Phase I trial is designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamic effects of the product when administered orally.

Sage chief executive officer Jeff Jonas said: “Advancing SAGE-718 into Phase I clinical development represents a significant achievement in broadening our clinical pipeline beyond GABA, with a new product development platform focused on a novel mechanism to modulate the NMDA receptor system.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"The top-line results from the Phase I trial are expected to be available in the second half of this year."

“Loss of NMDA function may have a significant impact in many neuro psych disorders, and SAGE-718 and our novel follow-on compounds have the potential to further extend our pipeline into a broad array of CNS indications."

According to the data from preclinical studies, SAGE-718 showed improved social behaviour in animal model with NMDA hypofunction, and mitigated deficits associated with behavioural and electrophysiological in a model with irregular cholesterol regulation.

The top-line results from the Phase I trial are expected to be available in the second half of this year.  

Sage develops medicines for central nervous system (CNS) disorders, targeting GABA and NMDA receptor systems.


Image: Sage Therapeutics' new trial for SAGE-718. Photo: courtesy of foto76/FreeDigitalPhotos.net.